Literature DB >> 8468357

Long-term culture of disaggregated rat osteoclasts: inhibition of bone resorption and reduction of osteoclast-like cell number by calcitonin and PTHrP[107-139].

A J Fenton1, T J Martin, G C Nicholson.   

Abstract

The isolated osteoclast bone resorption assay has proved to be a useful means of examining the response of mammalian and avian osteoclasts to a variety of stimuli. The assay has traditionally been performed over a period of 24 hours. By extending the duration of the osteoclast bone resorption assay, we have been able to assess the long-term effects of carboxyl-terminal parathyroid hormone-related protein (hPTHrP[107-139]), salmon calcitonin (sCT) and hPTH[1-34] on bone resorption and TRACP-positive osteoclast-like cell number. We found that, in control cultures over a period of up to 144 hours, the osteoclast-like cells not only remained viable but their numbers also increased. The number of mononucleated and multinucleated osteoclast-like cells doubled in the first 48 hours before stabilizing over the remainder of the incubation period. Osteoblasts also proliferated, resulting in a resorption response to hPTH[1-34] being evident from 48 hours onward. hPTHrP]107-139] persistently inhibited basal and PTH-stimulated bone resorption for at least 96-144 hours, whereas "escape" from the inhibitory effect of sCT was seen after 48-72 hours. Decreased numbers of both mononucleated and multinucleated TRACP-positive osteoclast-like cells were seen by 48 hours in cultures treated with sCT. In contrast, hPTHrP[107-139] reduced the number of mononuclear TRACP-positive cells with only a late effect on multinucleated cells. Furthermore, the increased number of osteoclast-like cells seen in response to hPTH[1-34] was inhibited by carboxyl-terminal PTHrP. In summary, this study indicates that the extended bone resorption assay system is a complex one where both osteoclastic resorption and osteoclast maturation are evident. Using this system, we have shown that hPTHrP[107-139] acts as a potent long-term inhibitor of osteoclastic bone resorption, without evidence of escape from its effect. Its action to reduce the number of mononucleated osteoclast-like cells suggests that it affects several aspects of osteoclast activity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8468357     DOI: 10.1002/jcp.1041550102

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  10 in total

1.  Plasma level monitoring of nasal salmon calcitonin in the rat by a heterogeneous two-site enzyme immunoassay.

Authors:  H Nakamuta; T Kohno; M Ichikawa; T Hoshino; K Watabe; M Koida
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

Review 2.  Historically significant events in the discovery of RANK/RANKL/OPG.

Authors:  T John Martin
Journal:  World J Orthop       Date:  2013-10-18

3.  Determination of the bioavailability of intranasal elcatonin in humans: development of a sandwich transfer enzyme immunoassay for elcatonin.

Authors:  T Kohno; N Murasugi; H Sakurai; K Watabe; H Nakamuta; M Koida; Y Sugie; T Ogouchi; T Inoue; M Yanaka; M Nomura; A Yanagawa
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

4.  A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo.

Authors:  V W Engleman; G A Nickols; F P Ross; M A Horton; D W Griggs; S L Settle; P G Ruminski; S L Teitelbaum
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

5.  Lack of significant effect of carboxyl-terminal parathyroid hormone-related peptide fragments on isolated rat and chick osteoclasts.

Authors:  R J Murrills; L S Stein; D W Dempster
Journal:  Calcif Tissue Int       Date:  1995-07       Impact factor: 4.333

Review 6.  Proteolytic Regulation of Parathyroid Hormone-Related Protein: Functional Implications for Skeletal Malignancy.

Authors:  Jeremy S Frieling; Conor C Lynch
Journal:  Int J Mol Sci       Date:  2019-06-08       Impact factor: 5.923

7.  Osteostatin Inhibits M-CSF+RANKL-Induced Human Osteoclast Differentiation by Modulating NFATc1.

Authors:  Lidia Ibáñez; Josep Nácher-Juan; María Carmen Terencio; María Luisa Ferrándiz; María José Alcaraz
Journal:  Int J Mol Sci       Date:  2022-08-01       Impact factor: 6.208

8.  Inhibition of miR-29 Activity in the Myeloid Lineage Increases Response to Calcitonin and Trabecular Bone Volume in Mice.

Authors:  Bongjin Shin; Henry C Hrdlicka; Anne M Delany; Sun-Kyeong Lee
Journal:  Endocrinology       Date:  2021-10-01       Impact factor: 5.051

9.  Parathyroid hormone-related peptide-depleted mice show abnormal epiphyseal cartilage development and altered endochondral bone formation.

Authors:  N Amizuka; H Warshawsky; J E Henderson; D Goltzman; A C Karaplis
Journal:  J Cell Biol       Date:  1994-09       Impact factor: 10.539

10.  Recombinant human parathyroid hormone related protein 1-34 and 1-84 and their roles in osteoporosis treatment.

Authors:  Hua Wang; Jingning Liu; Ying Yin; Jun Wu; Zilu Wang; Dengshun Miao; Wen Sun
Journal:  PLoS One       Date:  2014-02-06       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.